Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Is 65 to 80 years of age with controlled chronic illness~* agrees to participate in the study by giving written informed consent and cognitively competent as assessed by Mini-Mental State Examination~* for Part I: subject is living independently outside any long-term care facilities; for Part II: subject is expected to be a resident in a long term care facility (LTCF) including nursing homes with the exception of hospice care~* can be adequately followed for safety via visit or phone~* subject's routine safety lab results are within specified ranges~* has negative test results for HIV, Hepatitis B, and Hepatitis C~Exclusion Criteria:~* abdominal cancer/surgery within the past 6 months~* known or suspected immune diseases, e.g. diabetes~* any chronic or relapsing infections~* a fever at the time of immunization~* active vomiting or diarrhea at the time of immunization~* chronic diarrhea, irritable bowel syndrome, or inflammatory disease of intestinal or colon in the past 12 months~* subjects' spouses/cohabitants are not healthy or are immunocompromised; roommates in LTCFs are not healthy and/or do not agree to participate in the study~* cannot be adequately followed for safety via visit or phone~* any other clinically significant conditions that, in the investigators' opinion, would interfere with subject's participation in the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Part I, RotaTeq (Type: EXPERIMENTAL): 3 doses of RotaTeq
- Part I, placebo (Type: PLACEBO_COMPARATOR): 3 doses of placebo
- Part II, RotaTeq (Type: EXPERIMENTAL): 3 doses of RotaTeq
- Part II, RotaTeq and placebo (Type: EXPERIMENTAL): 1 dose of RotaTeq and 2 doses of placebo
- Part II, placebo (Type: PLACEBO_COMPARATOR): 3 doses of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).